Prescription drug · ANDA
Disopyramide Phosphate NDC 0093-3127
Disopyramide phosphate 100 mg/1 · Capsule · Oral · Teva Pharmaceuticals USA, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0093-3127-01 | 00093312701 | 100 CAPSULE in 1 BOTTLE (0093-3127-01)Marketed from Sep 30, 1990 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Disopyramide Phosphate
- Generic name (nonproprietary)
- disopyramide phosphate
- Active ingredients
- Disopyramide phosphate — 100 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 070101
- Marketing start
- Listing expires
- Identifiers
- Product ID 0093-3127_82d9eecb-bbb9-4daf-863e-362ab0cbadafSPL ID 82d9eecb-bbb9-4daf-863e-362ab0cbadafSPL set ID 11a68e26-d2e4-48f6-ba0f-9bdd5778f25aRxCUI 309958, 309960UNII N6BOM1935WUPC 0300933129015, 0300933127011
- Pharmacologic class
- Antiarrhythmic
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400093312701followed by a unit qualifier and the quantityPackage 00093-3127-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrh…
Excerpt only. Read the full label for complete information.